Peackbridge invested €900,000 into the Growing Biotechnology Company. Karjalohja, Finland, 08.04.2025 - KÄÄPÄ Biotech, a biotechnology company that researches, innovates and develops functional mushroom products, today announced it has closed a €900,000 strategic investment from PeakBridge, a pioneering global fund manager in agri-food and a member of the Edmond de Rothschild Private Equity partnership. The funding will be used to enable KÄÄPÄ Biotech to further scale its business to meet customer demand, and help bring functional mushroom ingredients to the forefront of global wellness.
KÄÄPÄ Biotech divisions include Nordic Mushrooms (supplier of B2B functional mushroom extract ingredients), KÄÄPÄ Mushrooms (supplier of B2C functional mushroom extract products), and KÄÄPÄ Forest (B2B chaga cultivator). Both Nordic Mushrooms and KÄÄPÄ Mushrooms use functional mushroom extract powders and liquids created using NordRelease™, KÄÄPÄ Biotech’s unique extraction process.
“The functional mushroom market continues to rapidly expand, and we’re seeing huge interest from a range of companies looking to get a start in this market, as well as a number of existing customers looking to scale their functional mushroom businesses,” said Eric Puro, KÄÄPÄ Biotech CEO and Co-Founder. “Over 180 companies, in more than 20 markets, have placed their trust in us to provide them with the world’s best quality functional mushroom extract ingredients. This investment will help drive a new phase of growth, as we continue to scale our business to match the increase in customer demands.”
Yoni Glickman, Managing Director of PeakBridge’s Seed Fund, FoodSparks®,"Health and nutrition have always been a key investment focus for us at PeakBridge, and in this space, functional mushrooms are emerging as a star ingredient. KÄÄPÄ Biotech stands out from the crowd with its innovative extraction technology and clinically validated products. Their focus on growing their own mushrooms also ensures traceability, stability in supply, and consistent quality - all critical to this fast growing sector. We're thrilled to bring their expert team to jump-start the next phase of growth."
As recently as September 2024, KÄÄPÄ Biotech announced it had opened a new state-of-the-art growing facility in Paimio, Finland. Today’s announcement further underlines the speed at which demand is growing for high quality functional mushroom extracts.
ABOUT KÄÄPÄ Biotech
KÄÄPÄ Biotech, a biotechnology company that researches, innovates and develops functional mushroom products, has three divisions: KÄÄPÄ Forest, KÄÄPÄ Mushrooms and Nordic Mushrooms. KÄÄPÄ Forest manages the largest chaga cultivation network in the world and promotes the versatile use of forests. KÄÄPÄ Mushrooms provides customers with Finnish-origin organic mushroom extracts. Nordic Mushrooms is a wholesale division providing customers with European organic certified mushroom extracts. Both Nordic Mushrooms and KÄÄPA Mushrooms use functional mushroom extract powders and liquids created using NordRelease™, KÄÄPÄ Biotech’s unique extraction process.
ABOUT PEAKBRIDGE
PeakBridge is a highly networked, global VC bridging the gap between bold innovation and real-world needs, to transform the future of food. From Seed to Series B, we invest in visionary pioneers with scalable, B2B, protectable technologies and positive impact at their core. Our global team includes pioneers of FoodTech investing, food industry experts and operators, scientists, and financiers. 360° experience, tailor-made to support our portfolio companies in making a long-term impact on our global food system.
Contact:
Alistair Hatch
CMO, KÄÄPÄ Biotech
Nurit Ben
Head of Communications, PeakBridge